153 related articles for article (PubMed ID: 36998343)
1. Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis.
Townsend MJ; Hodi FS; Grover S
ACG Case Rep J; 2023 Mar; 10(3):e01018. PubMed ID: 36998343
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in steroid-refractory immune-related pancreatitis: a case report.
Santoro A; Masini S; Cavina R; Tronconi MC; De Vincenzo F
Front Oncol; 2023; 13():1205720. PubMed ID: 37588091
[TBL] [Abstract][Full Text] [Related]
3. Immune-related colitis and pancreatitis treated with infliximab.
Ohwada S; Ishigami K; Yokoyama Y; Kazama T; Masaki Y; Takahashi M; Yoshii S; Yamano HO; Chiba H; Nakase H
Clin J Gastroenterol; 2023 Feb; 16(1):73-80. PubMed ID: 36414888
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis.
Shivaraj K; Tchakarov A; Dong Y; Lin JS
Clin Kidney J; 2024 May; 17(5):sfae127. PubMed ID: 38803394
[TBL] [Abstract][Full Text] [Related]
5. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series.
Zhang RS; Padegimas A; Murphy KM; Evans PT; Peters CJ; Domenico CM; Vidula MK; Mather PJ; Cevasco M; Cohen RB; Carver JR; O'Quinn RP
Cardiooncology; 2021 Mar; 7(1):13. PubMed ID: 33785062
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
7. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.
Alouani E; Laparra A; Perret A; Sakkal M; Messayke S; Danlos FX; Ouali K; Hollebecque A; Even C; Ammari S; Baldini C; Champiat S; Besse B; Robert C; Guettier C; Samuel D; Lambotte O; De Martin E; Michot JM
Eur J Cancer; 2023 Nov; 193():113313. PubMed ID: 37748398
[TBL] [Abstract][Full Text] [Related]
9. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis.
Moodabagil M; Easterling R; Peng J; Abu-Sbeih H; Meara A; Donnelly E; Owen DH; Ho K
Oncologist; 2024 Jun; ():. PubMed ID: 38886156
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study.
Kou F; Li J; Cao Y; Peng Z; Xu T; Shen L; Gong J; Wang X
Front Oncol; 2023; 13():1285478. PubMed ID: 38090496
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
[TBL] [Abstract][Full Text] [Related]
13. Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course.
Burla J; Bluemel S; Biedermann L; Barysch MJ; Dummer R; Levesque MP; Gubler C; Morell B; Rogler G; Scharl M
Inflamm Intest Dis; 2020 Aug; 5(3):109-116. PubMed ID: 32999883
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
Matzen E; Bartels LE; Løgstrup B; Horskær S; Stilling C; Donskov F
Cardiooncology; 2021 Aug; 7(1):27. PubMed ID: 34365980
[TBL] [Abstract][Full Text] [Related]
15. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
Sayed Ahmed A; Abreo M; Thomas A; Chari ST
Curr Opin Gastroenterol; 2022 Sep; 38(5):516-520. PubMed ID: 35881977
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
Abu-Sbeih H; Tang T; Lu Y; Thirumurthi S; Altan M; Jazaeri AA; Dadu R; Coronel E; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):31. PubMed ID: 30728076
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis.
Zhang E; Kiely C; Sandanayake N; Tattersall S
JGH Open; 2021 May; 5(5):558-562. PubMed ID: 34013054
[TBL] [Abstract][Full Text] [Related]
18. Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report.
Moriyama S; Fukata M; Tatsumoto R; Kono M
Eur Heart J Case Rep; 2021 Jan; 5(1):ytab002. PubMed ID: 33644656
[TBL] [Abstract][Full Text] [Related]
19. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events.
Brongiel S; Rychalsky KL; Luon D; Johnson AR; Price C; Abdelghany O
Ann Pharmacother; 2023 Feb; 57(2):148-155. PubMed ID: 35656843
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.
Camard M; Besse B; Cariou PL; Massayke S; Laparra A; Noel N; Michot JM; Ammari S; Pavec JL; Lambotte O
Respir Med Res; 2022 Nov; 82():100969. PubMed ID: 36370683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
